Skip to main content

Advertisement

Log in

The Importance of Panitumumab in Radiotherapy Involving Head and Neck Region

  • Letter to the Editor
  • Published:
Journal of Maxillofacial and Oral Surgery Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Françoso A, Simioni PU (2017) Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Des Devel Ther 11:177–184. https://doi.org/10.2147/dddt.s119036 (eCollection 2017)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ferris RL, Geiger JL, Trivedi S, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, Clump DA, Bauman JE, Ohr JP, Gooding WE, Argiris A (2016) Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer. Ann Oncol 27(12):2257–2262. https://doi.org/10.1093/annonc/mdw428 (Epub 2016 Oct 11)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Patel SB, Gill D, Garrido-Laguna I (2016) Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. OncoTargets Ther 9:75–86

    Article  CAS  Google Scholar 

  4. Mesıa R, Henke M, Fortin A et al (2015) Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16(2):208–220

    Article  CAS  PubMed  Google Scholar 

  5. Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G et al (2015) Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16(2):221–232. https://doi.org/10.1016/S1470-2045(14)71200-8 (Epub 2015 Jan 15)

    Article  CAS  PubMed  Google Scholar 

  6. Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, FitzGerald TJ, Childs TJ, Montenegro A, O’Sullivan B, Parulekar WR (2016) Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: a randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2016.4510 (Epubahead of print)

    Article  PubMed  Google Scholar 

  7. Pajares B, Trigo JM, Toledo MD, Álvarez M, González-Hermoso C, Rueda A, Medina JA, de Luque V, Jerez JM, Alba E (2013) Differential out come of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC Cancer 18(13):26. https://doi.org/10.1186/1471-2407-13-26

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yasemin Benderli Cihan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cihan, Y.B. The Importance of Panitumumab in Radiotherapy Involving Head and Neck Region. J. Maxillofac. Oral Surg. 18, 159–160 (2019). https://doi.org/10.1007/s12663-018-1138-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12663-018-1138-8

Navigation